Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUPLEX-AD: JNJ-95475939 in Moderate to Severe Atopic Dermatitis
NCT06881251Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of JNJ-95475939 in atopic dermatitis (AD) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants with Eczema Area and Severity Index 75 Response at 24 weeks. Started Feb 2025; status: terminated.
02
Drugs
JNJ-95475939
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06881251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881251.